A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 in Women With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 12 Mar 2018
At a glance
- Drugs G1T-48 (Primary)
- Indications Breast cancer
- Focus Adverse reactions; First in man
- Sponsors G1 Therapeutics
- 06 Mar 2018 Status changed from planning to not yet recruiting.
- 23 Feb 2018 New trial record
- 21 Feb 2018 According to a G1 Therapeutics media release, an Investigative New Drug (IND) application to support this trial opened in the first quarter of 2018.